Contemporary Strategies for Treating Invasive Fungal Infections in Immunocompromised Patients - Module 2

ACPE Activity Number:  0204-0000-19-401-H01-P
Activity Date: January 15, 2019
Expiration Date: January 15, 2020
Activity Type: Application 
CE Credits: 1.0 hour
Activity Fee:Free of charge

Accreditation for Pharmacists

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Accreditation for Physicians

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This activity was planned to meet the educational needs of physicians, pharmacists, nurse practitioners, and physician assistants caring for patients at risk for invasive fungal infections.

Activity Overview

Morbidity and mortality associated with invasive fungal infections remain high despite the availability of novel antifungals and new therapeutic strategies. This activity explores invasive fungal infections in the format of a clinical case dialogue. The cases include factors to consider in the delivery of patient-specific treatments and illustrate real-life clinical scenarios that healthcare providers might encounter in the community. Faculty focus on the diagnosis, treatment, and outcomes of invasive fungal infections in immunocompromised patients. 

As the second of two modules in this series, this activity explores these challenges using patient cases.

For more background on these concepts view, Module 1

Learning Objectives

At the conclusion of this activity, participants should be able to

  • Apply diagnostic tests and techniques for diagnosing invasive fungal infections.
  • Indicate treatment plans for immunocompromised patients with suspected or confirmed fungal infections.
  • Devise interprofessional strategies for overcoming challenges in the community setting in diagnosing and treating immunocompromised patients with invasive fungal infections.

Faculty Information

Peggy L. Carver, Pharm.D., FCCP, FIDP
Associate Professor, College of Pharmacy
Clinical Pharmacist, Infectious Diseases
University of Michigan Health System
Ann Arbor, Michigan

Peggy Carver, Pharm.D., FCCP, FIDP is Associate Professor of Pharmacy in the Department of Clinical Sciences at the College of Pharmacy, and Clinical Pharmacist in Infectious Diseases at the University of Michigan in Ann Arbor, Michigan.

After completing her undergraduate degree in Biology at UCLA, Dr. Carver earned her Doctor of Pharmacy degree and completed a residency at the University of California School of Pharmacy in San Francisco, California, followed by fellowship in Infectious Diseases at Hartford Hospital in Hartford, Connecticut.

Dr. Carver’s research focuses on antifungal therapy, and the role of metal ions in the development of infectious diseases. She has previously served as President of the Society of Infectious Diseases Pharmacists and Chair of the ASHP Specialty Practice Group in Infectious Diseases. She is a recipient of the University of Michigan College of Pharmacy Teaching Excellence Award, the Phi Delta Chi Alumni Advisor Award, and was inducted as a fellow of the American College of Clinical Pharmacy (ACCP) and the Society of Infectious Diseases Pharmacists (SIDP). She has been an invited presenter at numerous national and international scientific meetings and continuing education conferences.

P.H. Chandrasekar, M.D., F.A.C.P., F.I.D.S.A.
Professor of Medicine
Chief, Division of Infectious Diseases
Professor, Medicine / Infectious Diseases
Wayne State University / Karmanos Cancer Center
Detroit, Michigan

Pranatharthi Chandrasekar, M.D., FACP, FIDSA is Chief of the Division of Infectious Diseases and Section Chief of Infectious Diseases at Karmanos Cancer Center in Detroit, Michigan. He is also Professor of Medicine in the Division of Infectious diseases at Wayne State University.

Dr. Chandrasekar completed his residency in Internal Medicine at the University of Louisville, Kentucky and Fellowship in Infectious Diseases at the Hahnemann University. His major interests have included epidemiology, prevention, diagnosis and management of infections including invasive fungal infections in immunocompromised hosts, particularly those with underlying cancer and those undergoing stem cell transplantation.

Dr. Chandrasekar has published extensively in these fields and has trained many individuals in the United States and overseas. Dr. Chandrasekar serves in the Editorial Board of several journals including the British Journal of Antimicrobial Chemotherapy.

 

Disclosures

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships. In this activity, only the individual below has disclosed a financial relationship. No other persons associated with this activity have disclosed any relevant financial relationships. 

P.H. Chandrasekar, M.D., F.A.C.P., F.I.D.S.A.

  • Astellas: speakers bureau

Claim CE Within 60 Days

To receive CE credit, complete the steps below within 60 days of completing the activity.

  1. View the entire presentation.
  2. Click "Complete Activity" on last slide to complete the evaluation and claim credit. 
  3. Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.

After the 60-day deadline, ASHP will no longer be able to report credit(s).

System Technical Requirements

This is an online activity consisting of slides with audio and pre and post assessments. View the system requirements.

Provided by ASHP
Supported by an educational grant from Merck